Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

EGFR mutation + PD-L1 overexpression

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

EGFR mutation + PD-L1 overexpression	Lung Adenocarcinoma	EGFR mutation + PD-L1 overexpression	Lung Adenocarcinoma	EGFR inhibitor Resistant: C3 – Early Trials EGFR inhibitor Resistant : C3	EGFR inhibitor Resistant: C3 – Early Trials EGFR inhibitor Resistant : C3
EGFR mutation + PD-L1 overexpression	Lung Adenocarcinoma	EGFR mutation + PD-L1 overexpression	Lung Adenocarcinoma	afatinib Resistant: C3 – Early Trials afatinib Resistant : C3	afatinib Resistant: C3 – Early Trials afatinib Resistant : C3
EGFR mutation + PD-L1 overexpression	Lung Adenocarcinoma	EGFR mutation + PD-L1 overexpression	Lung Adenocarcinoma	erlotinib Resistant: C3 – Early Trials erlotinib Resistant : C3	erlotinib Resistant: C3 – Early Trials erlotinib Resistant : C3
EGFR mutation + PD-L1 overexpression	Lung Adenocarcinoma	EGFR mutation + PD-L1 overexpression	Lung Adenocarcinoma	gefitinib Resistant: C3 – Early Trials gefitinib Resistant : C3	gefitinib Resistant: C3 – Early Trials gefitinib Resistant : C3
EGFR mutation + PD-L1 overexpression	Non Small Cell Lung Cancer	EGFR mutation + PD-L1 overexpression	Non Small Cell Lung Cancer	EGFR inhibitor Resistant: C3 – Early Trials EGFR inhibitor Resistant : C3	EGFR inhibitor Resistant: C3 – Early Trials EGFR inhibitor Resistant : C3
EGFR mutation + PD-L1 overexpression	Non Small Cell Lung Cancer	EGFR mutation + PD-L1 overexpression	Non Small Cell Lung Cancer	pembrolizumab Resistant: C3 – Early Trials pembrolizumab Resistant : C3	pembrolizumab Resistant: C3 – Early Trials pembrolizumab Resistant : C3
EGFR mutation + PD-L1 overexpression	Non Small Cell Lung Cancer	EGFR mutation + PD-L1 overexpression	Non Small Cell Lung Cancer	osimertinib Resistant: C3 – Early Trials osimertinib Resistant : C3	osimertinib Resistant: C3 – Early Trials osimertinib Resistant : C3
EGFR mutation + PD-L1 overexpression	Non Small Cell Lung Cancer	EGFR mutation + PD-L1 overexpression	Non Small Cell Lung Cancer	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3